1. Show article details.

    GSK hopes big clinical trial can breath new life into lung drug

    Reuters – 11:47 AM ET 08/13/2015

    * Results of SUMMIT trial with Breo due as early as Sept. * Drug could be first to extend lives in COPD. * Billions of dollars riding on positive outcome. * U.S. partner Theravance (THRX) eligible for royalties on sales. By Ben Hirschler.

  2. Show article details.

    GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With Asthma

    Market Wire – 4:14 PM ET 08/06/2015

    08/06/15 -- GSK and Theravance, Inc. (THRX) announce the approval in Canada of BREO® ELLIPTA® for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. BREO® ELLIPTA® is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol.

  3. Show article details.

    Theravance Reports Second Quarter 2015 Financial Results

    Market Wire – 4:05 PM ET 07/29/2015

    07/29/15 -- Theravance, Inc. (THRX) today reported financial results for the second quarter ended June 30, 2015. Theravance (THRX) also announced that the company's Board of Directors has declared a $0.25 per share cash dividend to be paid on September 30, 2015 to stockholders of record as of the close of business on September 10, 2015.

  4. Show article details.

    Theravance to Report Second Quarter 2015 Financial Results on July 29, 2015

    Market Wire – 4:05 PM ET 07/22/2015

    07/22/15 -- Theravance, Inc. (THRX) announced today that it will report financial results for the second quarter ended June 30, 2015 after market close on Wednesday, July 29, 2015. To participate in the live call by telephone, please dial 837-3908 from the U.S., or 890-8166 for international callers.

  5. Show article details.

    Biotechnology Sector Stocks Technical Coverage -- Amgen, Exelixis, XOMA Corp., Theravance, and NewLink Genetics

    PR Newswire – 9:22 AM ET 07/22/2015

    NEW YORK, July 22, 2015 Equity Research Institute has initiated coverage on the following equities: Amgen Inc. (AMGN), Exelixis Inc. (EXEL), XOMA Corporation (XOMA), Theravance Inc. (THRX), and NewLink Genetics Corporation.

  6. Show article details.

    Theravance, Inc. Appoints Michael Faerm as Chief Business Officer

    Market Wire – 4:05 PM ET 07/13/2015

    07/13/15 -- Theravance, Inc. (THRX) today announced the appointment of Michael E. Faerm as Senior Vice President and Chief Business Officer. "Michael brings a unique perspective with his depth and breadth of experience in the biopharmaceutical industry, equity research and investment banking.

  7. Show article details.

    Theravance to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference

    Market Wire – 4:05 PM ET 05/07/2015

    05/07/15 -- Theravance, Inc. (THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2015 Healthcare Conference on Wednesday, May 13, 2015 at 1:00 p.m. PDT.

  8. Show article details.

    Theravance Reports First Quarter 2015 Financial Results

    Market Wire – 4:05 PM ET 05/06/2015

    05/06/15 -- Theravance, Inc. (THRX) today reported financial results for the first quarter ended March 31, 2015. Theravance (THRX) also announced that the company's Board of Directors has declared a $0.25 per share cash dividend to be paid on June 30, 2015 to stockholders of record as of the close of business on June 12, 2015.

  9. Show article details.

    FDA Approves BREO(R) ELLIPTA(R) for the Treatment of Adults With Asthma in the US

    Market Wire – 3:17 PM ET 04/30/2015

    04/30/15 -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) today announced that the US Food and Drug Administration has approved BREO® ELLIPTA® for the once-daily treatment of asthma in patients aged 18 years and older. Breo is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol.

  10. Show article details.

    Theravance to Report First Quarter 2015 Financial Results on May 6, 2015

    Market Wire – 4:05 PM ET 04/29/2015

    04/29/15 -- Theravance, Inc. (THRX) announced today that it will report financial results for the first quarter ended March 31, 2015 after market close on Wednesday, May 6, 2015. To participate in the live call by telephone, please dial 837-3908 from the U.S., or 890-8166 for international callers.

  11. Show article details.

    GSK and Theravance Announce Outcome of US FDA Advisory Committee on BREO(R) ELLIPTA(R) in Asthma

    Market Wire – 5:55 PM ET 03/19/2015

    03/19/15 -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) today announced the outcome of the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the United States Food and Drug Administration regarding the supplemental New Drug Application for BREO® ELLIPTA® as a once-daily inhaled treatment for asthma in patients aged 12 years ...

  12. Show article details.

    Theravance Announces Trading in Common Stock Halted

    Market Wire – 7:05 AM ET 03/19/2015

    03/19/15 -- Theravance, Inc. (THRX) announced today that NASDAQ halted trading of the Company's common stock this morning, March 19, 2015. BREO® ELLIPTA® is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2 agonist vilanterol, administered using the ELLIPTA® inhaler.

Page:

Today's and Upcoming Events

  • Sep
    8

    THRX ex-Dividend for $0.25 on 9/8/2015

    • Announce Date: 7/29/2015
    • Record Date: 9/10/2015
    • Pay Date: 9/30/2015
  • Oct
    29

    THRX to announce Q3 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Jul
    29

    THRX Earnings Conference Call at 5:00 PM Listen

  • Jul
    29

    THRX to announce Q2 earnings

    • Next earnings date: 10/29/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.